Ambu A/S (CPH:AMBUB), a developer, producer and marketer of life-saving equipment, announced on Tuesday the receipt of US FDA clearance for disposable colonoscope in the US.
With this milestone, Ambu said it is cleared to address the over 15 million annual procedure market for colonoscopy in the US.
Currently, Ambu operates in the field of single-use endoscopy for pulmonary (visualisation of the airways) with aScope and has sold more than 700,000 aScopes since the launch in 2013.
Ambu provides professional diagnostic, life supporting and training equipment. Its products are used for respiratory support and cardiopulmonary resuscitation, immobilisation and protection against infections. The company sells to hospitals, rescuers, armed forces and industry.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT